This report from Arnau Valdovinos, published in Cannareporter, 27 February 2026.
Something has shifted in how cannabis capital moves around the world.
After years of scarcity in cannabis capital markets, a new consolidation wave is taking shape — and it looks very different from the last one.
The deals landing in late 2025 and early 2026 are not chasing regulatory promises or untested business plans: they’re targeting revenue-generating companies with proven delivery at scale, established supply chains, and validated market access.
Valuations still reflect regulatory upside — premiums are higher where recreational optionality or multi-market expansion is on the table — but the floor has moved: in a more mature industry, buyers want to see the revenue before they write the cheque. The capital flows tell us where the market is heading.
United States: political signals, debt, and brand building
The situation in the US changed meaningfully in December 2025, when Trump signed an executive order that determined the reclassification of cannabis from Schedule I to Schedule IIIThe move doesn’t legalise cannabis federally, but it sends a clear normalisation signal — and it could eventually eliminate the punishing 280E tax burden that has squeezed operator margins for years.
Banking reform, long stalled around the SAFER Banking Actgained fresh political momentum as a bipartisan coalition urged Congress to act, though Major banks remain reluctant to serve cannabis businesses.
Against that backdrop, the biggest deal flow signal was the debt wave. Curaleaf’s US$500m note offering Curaleaf the largest in US cannabis history — was oversubscribed with 10 first-time cannabis lenders. Trulieve, GTI and TerrAscend followed with their own placements. In total, over US$960m in MSO debt was placed or refinanced in under a year. Institutional capital is entering cannabis credit at scale for the first time — and that changes the game for what comes next. Several major MSOs pruned non-core markets — and Ayr Wellness lost its assets across seven states in a creditor-driven foreclosure.
But mergers and acquisitions (M&A) also told a story of consolidation around brand, retail, and balance-sheet repair. Vireo Growth emerged as the most active acquirer, closing deals in five states — headlined by the US$132,7m Deep Roots Harvest acquisition in Nevada. PharmaCann absorbed LivWell’s 50+ dispensaries.. Wild merged with Grön to build the largest edibles brand spanning 16+ states. The pattern across all of them: brand equity and routes to shelves, not raw growing capacity.
Canada and Australia: strategic mergers and clinic roll-ups
No In Canada the deal flow shifted from distressed opportunism towards more strategic market share consolidation bets. In December Canopy Growth agreed to acquire MTL Cannabis for for C$179m enterprise value — the year’s largest Canadian transaction — explicitly targeting medical market leadership and
European flower supply. Retail consolidation picked up too, with SNDL and Pegasus Mercantile snapping up dozens of stores. The contrast with distressed assets was stark: Simply Solventless acquired Delta 9 Bio-Tech through a process of CCAA proceedings at nil, by a value of zero, the Auxly filed a C$4,64m stalking horse bid for Ayurcann from Ayurveda another CCAA extraction play — and Decibel sold its sold its Creston, BC property for C$2,5m,consolidating cultivation.
Australia told a similar story. In January, Cannatrek announced areverse takeover of Little Green Pharma through an A$85.1m scheme of arrangement (~8.5× EBITDA) — with Cannatrek shareholders taking ~60.5% of the combined group and creating a vertically integrated platform spanning GMP manufacturing, distribution, and clinics across Australia and Europe, with pro-forma revenue of A$112m.
LGP simultaneously divested its Western Australia production facility for A$7.8m in a sale-and-lease-back, redirecting capital towards Australian and European expansion. Clinic roll-ups multiplied, foreign capital arrived — Chemist Warehouse, Australia’s dominant pharmacy chain, reportedly emerged as frontrunner to acquire Astrid Dispensary — the clearest crossover yet into mainstream retail.
In both markets, the premium went to operators with integrated capabilities — compliant production, distribution reach, and patient access — not just to those with funded capacity.
Germany and Europe: where market access platforms attract investment.
Germany was the centre of gravity of European cannabis, with a post-legalisation M&A wave finally taking shape. Three Canadian-led deals laid down the clearest valuation benchmarks in the sector.
High Tide, Canada’s largest dispensary chain, took a majority stake in pharmacy distributor Remexian for €26.4m (3.6×) — distribution muscle in a fragmented medical market with roughly a dozen competitive distributors. And Organigram announced the acquisition of Sanity Group for €250m (~12.6×) — a full-platform bet combining brand, multi-market medical presence, and recreational optionality via the Swiss pilot.
Meanwhile, the Netherlands saw Cronos agreed to acquire cultivator CanAdelaar for €57,5m (2,4× EBITDA) — proven production at scale, but capped by a Dutch pilot framework, with no exports. The 2,4×–12,6× spread tells the story: proven production sets the baseline valuation, but platforms that layer compliance, brand, distribution, and regulatory positioning across multiple demand corridors carry a significant premium.
Around the same time, Enua secured a €25m credit facility from Deutsche Bank the first tier-one European bank cannabis debt facility — a milestone that shifts risk perception for the whole sector.
The same consolidation logic played out across the rest of Europe.
In the United Kingdom,CNX Therapeutics acquired Sativex’s global business to Jazz Pharmaceuticals a landmark pharma IP transfer — while GrowGroup completed the acquisition of Avida Medical consolidating import, manufacturing, and distribution under a single licensed platform.
In Spain,Torreal recapitalised EU-GMP cultivator Linneo Health, gaining majority control. Denmark saw Stenocare absorb CannGros, consolidating distribution capacity.
And France and Portugal continued attracting production investment — building the EU-GMP capacity that demand markets need, while the question of how to turn that capacity into market access remains open.
What this means for export-oriented producers
The deal data is clear: proven production capacity has real value, but the ceiling is set by market access. EU-GMP capacity will find buyers: Germany imported nearly 200 tonnes in 2025. Demand is rising across the UK, Poland, and emerging medical markets.
But international distribution remains volatile and fragmented — roughly a dozen competitive distributors per major demand market, some consolidation around clinic formularies and telemedicine verticals, and a long way for consolidation to go.
For export-oriented producers in Portugal, Canada, and elsewhere, the risk is commoditisation: becoming an interchangeable bulk supplier competing on price.
The opportunity is to build a market access platform from the production base — validated processes and product IP that travel across borders, supply chain partnerships in destination markets, brand deals, and compliance infrastructure that can serve as a gateway for international players.
That includes North American operators seeking entry into European demand markets, as seen in recent entries.
In the new phase, what counts is not just the capacity to produce, but to do so in compliance and at scale, funnelling demand into mass markets. The next consolidation cycle will reward those who’ve built accordingly.
#
